213 related articles for article (PubMed ID: 32323484)
1. Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review.
Zehentmayr F; Grambozov B; Kaiser J; Fastner G; Sedlmayer F
Thorac Cancer; 2020 Jun; 11(6):1375-1385. PubMed ID: 32323484
[TBL] [Abstract][Full Text] [Related]
2. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial.
Wu KL; Jiang GL; Liao Y; Qian H; Wang LJ; Fu XL; Zhao S
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1336-44. PubMed ID: 14630271
[TBL] [Abstract][Full Text] [Related]
3. Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer.
Kepka L; Tyc-Szczepaniak D; Bujko K
J Thorac Oncol; 2009 Jul; 4(7):853-61. PubMed ID: 19487965
[TBL] [Abstract][Full Text] [Related]
4. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
[TBL] [Abstract][Full Text] [Related]
5. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
Rosenzweig KE; Fox JL; Yorke E; Amols H; Jackson A; Rusch V; Kris MG; Ling CC; Leibel SA
Cancer; 2005 May; 103(10):2118-27. PubMed ID: 15830346
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer.
Nieder C; Imingen KS; Mannsåker B; Yobuta R; Haukland E
Radiat Oncol; 2020 May; 15(1):91. PubMed ID: 32357936
[TBL] [Abstract][Full Text] [Related]
7. Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.
Westover KD; Loo BW; Gerber DE; Iyengar P; Choy H; Diehn M; Hughes R; Schiller J; Dowell J; Wardak Z; Sher D; Christie A; Xie XJ; Corona I; Sharma A; Wadsworth ME; Timmerman R
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):72-81. PubMed ID: 26279026
[TBL] [Abstract][Full Text] [Related]
8. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
[TBL] [Abstract][Full Text] [Related]
9. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma.
Bradley JD; Ieumwananonthachai N; Purdy JA; Wasserman TH; Lockett MA; Graham MV; Perez CA
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):49-57. PubMed ID: 11777621
[TBL] [Abstract][Full Text] [Related]
10. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
Rosenzweig KE; Mychalczak B; Fuks Z; Hanley J; Burman C; Ling CC; Armstrong J; Ginsberg R; Kris MG; Raben A; Leibel S
Cancer J; 2000; 6(2):82-7. PubMed ID: 11069224
[TBL] [Abstract][Full Text] [Related]
11. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
12. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
[TBL] [Abstract][Full Text] [Related]
13. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy.
Belderbos JS; Heemsbergen WD; De Jaeger K; Baas P; Lebesque JV
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):126-34. PubMed ID: 16904518
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy for lung cancer: target splitting by asymmetric collimation enables reduction of radiation doses to normal tissues and dose escalation.
Wurstbauer K; Deutschmann H; Kranzinger M; Merz F; Rahim H; Sedlmayer F; Kogelnik HD
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):333-41. PubMed ID: 10760428
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer.
Sim S; Rosenzweig KE; Schindelheim R; Ng KK; Leibel SA
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):660-5. PubMed ID: 11597806
[TBL] [Abstract][Full Text] [Related]
16. An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.
Wanet M; Delor A; Hanin FX; Ghaye B; Van Maanen A; Remouchamps V; Clermont C; Goossens S; Lee JA; Janssens G; Bol A; Geets X
Strahlenther Onkol; 2017 Oct; 193(10):812-822. PubMed ID: 28733723
[TBL] [Abstract][Full Text] [Related]
17. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
Socinski MA; Morris DE; Halle JS; Moore DT; Hensing TA; Limentani SA; Fraser R; Tynan M; Mears A; Rivera MP; Detterbeck FC; Rosenman JG
J Clin Oncol; 2004 Nov; 22(21):4341-50. PubMed ID: 15514375
[TBL] [Abstract][Full Text] [Related]
18. Intensity-modulated radiotherapy for locally advanced non-small-cell lung cancer: a dose-escalation planning study.
Lievens Y; Nulens A; Gaber MA; Defraene G; De Wever W; Stroobants S; Van den Heuvel F;
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):306-13. PubMed ID: 20888706
[TBL] [Abstract][Full Text] [Related]
19. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
Zehentmayr F; Söhn M; Exeli AK; Wurstbauer K; Tröller A; Deutschmann H; Fastner G; Fussl C; Steininger P; Kranzinger M; Belka C; Studnicka M; Sedlmayer F
Radiat Oncol; 2015 May; 10():121. PubMed ID: 26018527
[TBL] [Abstract][Full Text] [Related]
20. Potential of adaptive radiotherapy to escalate the radiation dose in combined radiochemotherapy for locally advanced non-small cell lung cancer.
Guckenberger M; Wilbert J; Richter A; Baier K; Flentje M
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):901-8. PubMed ID: 20708850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
